New hope for Tough-to-Treat lymphoma: early trial tests powerful drug cocktail
NCT ID NCT01959698
Summary
This early-stage study is testing a new combination of drugs for patients with an aggressive type of lymphoma (DLBCL) that has returned or not responded to previous treatment. Researchers are adding a drug called carfilzomib to a standard chemotherapy regimen to see if it's safe, find the best dose, and check if it helps shrink tumors. The goal is to better control the disease, potentially preparing patients for a stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.